TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27046309

Group type: EXPERIMENTAL
Intervention: Cariprazine 2-4.5 mg/d
Number of subjects: 819

Group type: EXPERIMENTAL
Intervention: Cariprazine 1-2 mg/d
Number of subjects: 819

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 819
Study: 24178787

Group type: EXPERIMENTAL
Intervention: tesamorelin
Number of subjects: 39

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 39
Study: 22168256

Group type: COMPARATOR
Intervention: Wearing one of seven respirators or a medical mask for 8 hr (or as long as tolerable) with interposed doffing periods every 2 hr
Number of subjects: 27
Study: 21084615

Group type: EXPERIMENTAL
Intervention: Monetary punishment for recall performance
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Monetary reward for recall performance
Number of subjects: 0
Study: 18480687

Group type: EXPERIMENTAL
Intervention: Bupropion SR 150 mg/d
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Bupropion SR 300 mg/d
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Bupropion SR 400 mg/d
Number of subjects: 300

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study: 16317652

Group type: EXPERIMENTAL
Intervention: Test rinse (IND 61,164)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 12583945

Group type: EXPERIMENTAL
Intervention: Admission cardiotocography (20 min)
Number of subjects: 8580

Group type: COMPARATOR
Intervention: Usual care (intermittent auscultation only)
Number of subjects: 8580

Group type: EXPERIMENTAL
Intervention: Admission cardiotocography
Number of subjects: 8580
Study: 11395344

Group type: EXPERIMENTAL
Intervention: Behaviour management training programme
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 62
Study: 9918643

Group type: EXPERIMENTAL
Intervention: GC Fuji Ortho glass ionomer cement (GC Industrial, Tokyo, Japan)
Number of subjects: 48

Group type: COMPARATOR
Intervention: System 1+ composite resin (Ormco, Glendora, CA)
Number of subjects: 48
Study: 7941663

Group type: EXPERIMENTAL
Intervention: salbutamol 0.1%
Number of subjects: 14

Group type: COMPARATOR
Intervention: normal saline
Number of subjects: 14
Study: 3793916

Group type: EXPERIMENTAL
Intervention: Oral morphine, every 4 h
Number of subjects: 25

Group type: COMPARATOR
Intervention: Injected meperidine (Demerol), every 3-4 h pro re nata
Number of subjects: 25
Study: 31232139

Group type: EXPERIMENTAL
Intervention: High-dose atorvastatin (40 mg/d) combined with aspirin (100 mg/d)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Standard dose atorvastatin (20 mg/d) combined with aspirin (100 mg/d)
Number of subjects: 120
Study: 26929396

Group type: EXPERIMENTAL
Intervention: Non-invasive ventilation (NIV)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Positive expiratory pressure (PEP)
Number of subjects: 32
Study: 25270609

Group type: EXPERIMENTAL
Intervention: Single port/incision laparoscopic surgery (SPILS)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Standard three-port laparoscopic surgery
Number of subjects: 79
Study: 22952201

Group type: EXPERIMENTAL
Intervention: Fully supervised center‐based exercise (FS)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Minimally supervised home‐based exercise (MS)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Nonexercise controls (C)
Number of subjects: 119
Study: 22046814

Group type: EXPERIMENTAL
Intervention: 4 mg glimepiride
Number of subjects: 24
Study: 18981033

Group type: EXPERIMENTAL
Intervention: BNP-guided treatment (measured BNP concentrations at 12 and 24 hours after the first dose of indomethacin, withholding doses if BNP <100 pg/ml)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (standard indomethacin treatment without BNP guidance)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: BNP-guided treatment
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study: 16360311

Group type: EXPERIMENTAL
Intervention: Depot zuclopenthixol
Number of subjects: 46

Group type: COMPARATOR
Intervention: Oral zuclopenthixol
Number of subjects: 46
Study: 15336231

Group type: EXPERIMENTAL
Intervention: CST-17 (2.0 microg/kg/h iv over 120 min)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: CST-14 (2.0 microg/kg/h iv over 120 min)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: SS-14 (2.0 microg/kg/h iv over 120 min)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: CST-17
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: CST-14
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: SS-14
Number of subjects: 6
Study: 11910616

Group type: EXPERIMENTAL
Intervention: Transdermal progesterone cream (16, 32, or 64 mg daily for 14 days)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Transdermal estrogen (continuous for 28-day cycle)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Salivary progesterone levels
Number of subjects: 27
Study: 9295821

Group type: EXPERIMENTAL
Intervention: Diaspirin cross-linked hemoglobin (DCLHb)
Number of subjects: 14
Study: 8116856

Group type: EXPERIMENTAL
Intervention: Lysine acetylsalicylate (162 mg)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Furosemide (18 mg)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Combination of lysine acetylsalicylate and furosemide
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 31764785

Group type: EXPERIMENTAL
Intervention: Rivaroxaban (10 mg/day, orally)
Number of subjects: 423

Group type: EXPERIMENTAL
Intervention: LMWH (Enoxaparin, 4000 anti-Xa IU/day, subcutaneous injection)
Number of subjects: 423

Group type: COMPARATOR
Intervention: Control (no anticoagulant)
Number of subjects: 423
Study: 28499376

Group type: EXPERIMENTAL
Intervention: Mindfulness-based childbirth preparation course (MIL)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard childbirth preparation course (Control)
Number of subjects: 30
Study: 25398453

Group type: EXPERIMENTAL
Intervention: Lapatinib
Number of subjects: 121

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121
Study: 21985749

Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training (IMT)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo Inspiratory Muscle Training (P-IMT)
Number of subjects: 13
Study: 21535997

Group type: EXPERIMENTAL
Intervention: 7,000 lux fluorescent bright white light
Number of subjects: 27

Group type: COMPARATOR
Intervention: 70 lux dim red (placebo) light
Number of subjects: 27
Study: 18270369

Group type: EXPERIMENTAL
Intervention: High folate intake
Number of subjects: 26556

Group type: EXPERIMENTAL
Intervention: Vitamin B6, vitamin B12, and methionine intakes
Number of subjects: 26556
Study: 16480742

Group type: EXPERIMENTAL
Intervention: Paced Visual Serial Addition Task (PVSAT) in CIS patients
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Paced Visual Serial Addition Task (PVSAT) in CDMS patients
Number of subjects: 36

Group type: COMPARATOR
Intervention: Paced Visual Serial Addition Task (PVSAT) in healthy controls
Number of subjects: 36

Group type: COMPARATOR
Intervention: Paced Auditory Serial Addition Task (PASAT)
Number of subjects: 36
Study: 12911658

Group type: EXPERIMENTAL
Intervention: Ecabet sodium 1 g b.i.d and cimetidine 400 mg b.i.d.
Number of subjects: 200

Group type: COMPARATOR
Intervention: Cimetidine 400 mg b.i.d. alone
Number of subjects: 200
Study: 11164441

Group type: EXPERIMENTAL
Intervention: Lipid-lowering drugs
Number of subjects: 2749

Group type: EXPERIMENTAL
Intervention: Therapeutic goal of total cholesterol < 5.0 mmol/l
Number of subjects: 2749

Group type: EXPERIMENTAL
Intervention: Therapeutic goal of total cholesterol < 4.5 mmol/l
Number of subjects: 2749
Study: 9280037

Group type: EXPERIMENTAL
Intervention: Wheat bran fibre supplement
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 8243794

Group type: EXPERIMENTAL
Intervention: 20 mg/day tenoxicam
Number of subjects: 36

Group type: COMPARATOR
Intervention: 100 mg/day diclofenac sodium
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Helicobacter pylori colonization
Number of subjects: 36
Study: 3511125

Group type: EXPERIMENTAL
Intervention: A‐mode ultrasound
Number of subjects: 75

Group type: COMPARATOR
Intervention: Waters view radiographs
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Cough and rhinorrhea symptoms
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Headache
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Copious rhinorrhea
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Purulent rhinorrhea
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Middle ear abnormalities
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Tympanometry findings
Number of subjects: 75
Study: 31515531

Group type: EXPERIMENTAL
Intervention: Mismatch-repair-deficient strain
Number of subjects: 100

Group type: COMPARATOR
Intervention: Mismatch-repair-proficient strain
Number of subjects: 100
Study: 29305240

Group type: EXPERIMENTAL
Intervention: RUSF+Arg/Citr (Arg, 0.2 g/kg/day; Citr, 0.1 g/kg/day) with daily chloroquine (50 mg)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Base RUSF with weekly chloroquine (150 mg)
Number of subjects: 29
Study: 27357093

Group type: EXPERIMENTAL
Intervention: Fructose-sweetened beverages (4 servings/d)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Glucose-sweetened beverages (4 servings/d)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: HFCS-sweetened beverages (4 servings/d)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Standardized diet ad libitum
Number of subjects: 24
Study: 24886344

Group type: EXPERIMENTAL
Intervention: Interprofessional nurse-led mental health promotion intervention for six months
Number of subjects: 142
Study: 22435370

Group type: EXPERIMENTAL
Intervention: REGN727 (50 mg)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: REGN727 (100 mg)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: REGN727 (150 mg)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 132
Study: 20521869

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) with latex extract
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 17239657

Group type: EXPERIMENTAL
Intervention: sumanirole 0.5mg
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: sumanirole 1.0mg
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: sumanirole 2.0mg
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: sumanirole 4.0mg
Number of subjects: 270

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: sumanirole (all doses)
Number of subjects: 270
Study: 14971965

Group type: EXPERIMENTAL
Intervention: 5.0 g Cr + 18 g dextrose taken 4 times per day for 5 days
Number of subjects: 10

Group type: COMPARATOR
Intervention: 18 g dextrose as placebo (PL)
Number of subjects: 10
Study: 11354858

Group type: EXPERIMENTAL
Intervention: Patellar tendon (PT) autograft
Number of subjects: 65

Group type: COMPARATOR
Intervention: Hamstring (HS) autograft
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Both PT and HS groups
Number of subjects: 65
Study: 9389813

Group type: EXPERIMENTAL
Intervention: Cyproterone acetate, 12.5 mg, and T undecanoate, 80 mg, administered orally twice daily for 16 weeks
Number of subjects: 8
Study: 7697688

Group type: EXPERIMENTAL
Intervention: Enteric-coated (EC) naproxen tablets 500 mg twice daily
Number of subjects: 24

Group type: COMPARATOR
Intervention: Standard naproxen tablets 500 mg twice daily
Number of subjects: 24
Study: 2959197

Group type: EXPERIMENTAL
Intervention: Teicoplanin 200 mg i.v. + Rifampin 600 mg orally
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Teicoplanin 400 mg i.v. + Rifampin 300 mg i.v.
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Teicoplanin-rifampin combination
Number of subjects: 10

Group type: COMPARATOR
Intervention: Teicoplanin
Number of subjects: 10
Study: 30175648

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT), 8 weekly sessions of 45-60 minutes each.
Number of subjects: 74

Group type: COMPARATOR
Intervention: Control group (no CBT).
Number of subjects: 74
Study: 27302208

Group type: EXPERIMENTAL
Intervention: Daily vitamin D3 supplementation (2000 IU/D)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Monthly vitamin D3 supplementation (40,000 IU/month)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 120
Study: 27022005

Group type: EXPERIMENTAL
Intervention: Self-imagination (SI)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Semantic processing
Number of subjects: 20

Group type: COMPARATOR
Intervention: Self-referential strategies
Number of subjects: 20
Study: 24495415

Group type: EXPERIMENTAL
Intervention: Thermal welding tonsillectomy
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Cold dissection tonsillectomy
Number of subjects: 40
Study: 22381643

Group type: EXPERIMENTAL
Intervention: Methionine intake (quartiles)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Alanine intake (quartiles)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Threonine intake (quartiles)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Histidine intake (quartiles)
Number of subjects: 92
Study: 19515415

Group type: EXPERIMENTAL
Intervention: Aleglitazar 50 mug
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: Aleglitazar 150 mug
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: Aleglitazar 300 mug
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: Aleglitazar 600 mug
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: Pioglitazone 45 mg
Number of subjects: 332

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 332
Study: 17475412

Group type: EXPERIMENTAL
Intervention: Antiandrogenic oral contraceptive (30 microg ethinyl estradiol combined with 3 mg drospirenone) for 3 months
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (healthy controls)
Number of subjects: 21
Study: 15675932

Group type: EXPERIMENTAL
Intervention: Caudal S(+)‐ketamine 1 mg.kg(‐1) (group K)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Caudal S(+)‐ketamine 0.5 mg.kg(‐1) plus neostigmine 10 microg.kg(‐1) (group KN)
Number of subjects: 40
Study: 11860044

Group type: EXPERIMENTAL
Intervention: General enhancement classroom program
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: General enhancement plus small-group peer-skills training
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: General enhancement plus small-group peer-skills training plus family intervention
Number of subjects: 1500

Group type: COMPARATOR
Intervention: No-treatment control
Number of subjects: 1500
Study: 10030482

Group type: COMPARATOR
Intervention: Standard didactic presentation training for staff at four agencies
Number of subjects: 15425

Group type: EXPERIMENTAL
Intervention: Intensive training paired with standard didactic presentation for staff at five agencies
Number of subjects: 15425

Group type: COMPARATOR
Intervention: Family therapy services
Number of subjects: 15425

Group type: COMPARATOR
Intervention: Family support services
Number of subjects: 15425

Group type: COMPARATOR
Intervention: Educational or support programs for families
Number of subjects: 15425
Study: 7673533

Group type: EXPERIMENTAL
Intervention: Preventive intervention (home-based parent training and school-based social skills training)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 0
Study: 1692944

Group type: EXPERIMENTAL
Intervention: Bunazosin (2.0 mg t.i.d.)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Propranolol (40 mg t.i.d.)
Number of subjects: 16
Study: 6153847

Group type: EXPERIMENTAL
Intervention: L-lysine monohydrochloride 1000 mg daily
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 65
Study: 31471421

Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Number of subjects: 1

Group type: COMPARATOR
Intervention: Hydroxyurea
Number of subjects: 1
Study: 27898479

Group type: EXPERIMENTAL
Intervention: Pressing group (n = 30)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Nonpressing group (n = 30)
Number of subjects: 64
Study: 25452139

Group type: EXPERIMENTAL
Intervention: FF/UMEC 125 mcg
Number of subjects: 421

Group type: EXPERIMENTAL
Intervention: FF/UMEC 250 mcg
Number of subjects: 421

Group type: EXPERIMENTAL
Intervention: FF/UMEC 31.25 mcg
Number of subjects: 421

Group type: EXPERIMENTAL
Intervention: FF/UMEC 62.5 mcg
Number of subjects: 421

Group type: COMPARATOR
Intervention: FF
Number of subjects: 421
Study: 23788218

Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 148

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 148

Group type: COMPARATOR
Intervention: Radiotherapy
Number of subjects: 148
Study: 21849168

Group type: EXPERIMENTAL
Intervention: Robot-assisted planar reaching (gravity compensated)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Combined planar with vertical robot-assisted reaching
Number of subjects: 62

Group type: COMPARATOR
Intervention: Intensive conventional arm exercise program
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Planar robot-assisted exercise (for participants with greater motor impairment)
Number of subjects: 62
Study: 18956153

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (5 mg elemental zinc daily for 6 months)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 17960961

Group type: EXPERIMENTAL
Intervention: Aripiprazole (15 or 30 mg/day)
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 161

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 161
Study: 14733999

Group type: EXPERIMENTAL
Intervention: PSA between 1.0 and 2.99 ng/ml with f/t PSA ratio < or =20%; 249 biopsies indicated, 159 performed (acceptance 63.9%)
Number of subjects: 1097

Group type: EXPERIMENTAL
Intervention: PSA between 3.0 and 3.99 ng/ml; 72 men recommended for biopsy, 56 performed (77.8%)
Number of subjects: 1097

Group type: EXPERIMENTAL
Intervention: Cancers detected in the study
Number of subjects: 1097
Study: 11524048

Group type: EXPERIMENTAL
Intervention: Cilostazol
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 9642018

Group type: EXPERIMENTAL
Intervention: Semantically complex verbs (e.g., run)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Semantically simpler verbs (e.g., go)
Number of subjects: 8
Study: 7916883

Group type: EXPERIMENTAL
Intervention: Hyperventilation of sulfur dioxide (SO2)-air
Number of subjects: 37

Group type: COMPARATOR
Intervention: Hyperventilation of cold air
Number of subjects: 37
Study: 2379442

Group type: EXPERIMENTAL
Intervention: 250 g of glucose daily with no phosphorus
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 250 g of glucose with 7.5 mmol of phosphate daily
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 500 g of glucose with 15 mmol of phosphate daily
Number of subjects: 16
Study: 373776

Group type: EXPERIMENTAL
Intervention: Euphyllin retard (theophylline ethylenediamine oblong tablets) at a dose of 2 X 700 mg/d
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Euphyllin retard (theophylline ethylenediamine oblong tablets) at a dose of 2 X 350 mg/d
Number of subjects: 40
Study: 29566588

Group type: EXPERIMENTAL
Intervention: ReSET (Strategic Executive Treatment)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Cogniplus (computerised repetitive practice training for attention)
Number of subjects: 43
Study: 31157708

Group type: EXPERIMENTAL
Intervention: Topical analgesic gel
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Participants with DOMS
Number of subjects: 32
Study: 28494914

Group type: EXPERIMENTAL
Intervention: 1mg oral melatonin daily 1 hour before bedtime one day before surgery and for another 5 consecutive days postoperatively
Number of subjects: 139

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 139
Study: 26249300

Group type: EXPERIMENTAL
Intervention: Telemedicine (8 sessions of behavioral activation therapy)
Number of subjects: 241

Group type: COMPARATOR
Intervention: Same-room treatment (8 sessions of behavioral activation therapy)
Number of subjects: 241
Study: 22540770

Group type: EXPERIMENTAL
Intervention: Ciclosporin (4 mg/kg/day)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Prednisolone (0.75 mg/kg/day)
Number of subjects: 140
Study: 21079147

Group type: EXPERIMENTAL
Intervention: Carboplatin (AUC 5) plus oral S-1 (40 mg/m2 twice per day) on days 1 to 14
Number of subjects: 564

Group type: COMPARATOR
Intervention: Carboplatin (AUC 6) plus paclitaxel (200 mg/m2) on day 1 every 21 days
Number of subjects: 564

Group type: EXPERIMENTAL
Intervention: Carboplatin and S-1
Number of subjects: 564

Group type: COMPARATOR
Intervention: Carboplatin and paclitaxel
Number of subjects: 564
Study: 19738339

Group type: EXPERIMENTAL
Intervention: Artemether-Lumefantrine (Coartem 20 mg/120 mg)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Chlorproguanil-Dapsone (Lapdap)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 100
Study: 15931654

Group type: EXPERIMENTAL
Intervention: Regional anaesthesia (RA)
Number of subjects: 51

Group type: COMPARATOR
Intervention: General anaesthesia (GA)
Number of subjects: 51
Study: 12851616

Group type: COMPARATOR
Intervention: Fenofibrate 200 mg/day (F group)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Fenofibrate 200 mg/day plus folic acid 10 mg/every other day (F+F group)
Number of subjects: 37
Study: 10381993

Group type: EXPERIMENTAL
Intervention: 1 mg nalmefene
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: 2 mg nalmefene
Number of subjects: 176

Group type: COMPARATOR
Intervention: 2 mg naloxone
Number of subjects: 176
Study: 8896541

Group type: EXPERIMENTAL
Intervention: High-titer vaccine
Number of subjects: 513

Group type: EXPERIMENTAL
Intervention: Low-titer vaccine
Number of subjects: 513

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 513
Study: 6359486

Group type: EXPERIMENTAL
Intervention: Ciramadol 20 mg
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Ciramadol 60 mg
Number of subjects: 180

Group type: COMPARATOR
Intervention: Codeine 60 mg
Number of subjects: 180
Study: 31672121

Group type: EXPERIMENTAL
Intervention: Presence of barriers in the participant's environment and multimorbidity
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pain on the VAS scale ≥3 points and older age
Number of subjects: 0
Study: 29787488

Group type: EXPERIMENTAL
Intervention: Scleral lenses with various initial post-lens tear thickness (PoLTT) values ranging from 74 to 543 μm
Number of subjects: 0